Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...

The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Financial writer sees Novo Nordisk's stock drop as a buying opportunity after disappointing trial results, citing strong ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

Barclays lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,050 and keeps an Overweight rating on the shares. The firm ...